tiprankstipranks
Trending News
More News >

Larimar Therapeutics’ nomlabofusp shows therapeutic potential in FA

Larimar Therapeutics (LRMR) announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin protein replacement therapy designed to address the underlying cause of Friedreich’s ataxia, or FA. These data were included in the briefing package reviewed by the FDA in support of potentially using skin FXN concentrations as a reasonably likely surrogate endpoint for Larimar’s registrational program seeking accelerated approval for nomlabofusp.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1